Therapeutic Potential of 5-HT2C Receptor Antagonists in the Treatment of Anxiety Disorders

被引：31

作者：

Wood, Martyn D. ^{[1
]}

机构：

[1] GlaxoSmithKline, Dept Biol, Psychiat Ctr Excellence Drug Discovery, New Frontiers Sci Pk,Third Ave, Harlow CM19 5AW, Essex CM19 5AW, England

来源：

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS | 2003年 / 2卷 / 06期

关键词：

5-hydroxytryptamine; 5-HT; anxiety; antagonists;

D O I：

10.2174/1568007033482698

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Anxiety disorders are the most common psychiatric illness affecting both adults and children. Following the observation that m-chlorophenylpiperazine(mCPP) induced anxiety-like states in patients and in animal models, it was shown that in man, mCPP behaves as a functionally selective agonist at the 5-hydroxytryptamine (5-HT)(2C) receptor. This caused much interest in the development of antagonists at the 5-HT2C receptor for the treatment of anxiety disorders. This review examines the pre-clinical and clinical evidence for a role of the 5-HT2C receptor in anxiety and evaluates the progress of compounds that target this therapeutic approach.

引用

页码：383 / 387

页数：5

共 76 条

[1]

ALTAMURA AC, 1989, INT J CLIN PHARM RES, V9, P197

[2]

BAKISH D, 1994, PSYCHOPHARMACOL BULL, V30, P53

[3] 5-HT RECEPTORS AS TARGETS FOR THE DEVELOPMENT OF NOVEL ANXIOLYTIC DRUGS - MODELS, MECHANISMS AND FUTURE-DIRECTIONS [J].

BARRETT, JE ;

VANOVER, KE .

PSYCHOPHARMACOLOGY, 1993, 112 (01) :1-12

[4]

BILL DJ, 1995, BRIT J PHARMACOL, V116, pP217

[5] RS-102221: A novel high affinity and selective, 5-HT2C receptor antagonist [J].

Bonhaus, DW ;

Weinhardt, KK ;

Taylor, M ;

Desouza, A ;

Mcneeley, PM ;

Szczepanski, K ;

Fontana, DJ ;

Trinh, J ;

Rocha, CL ;

Dawson, MW ;

Flippin, LA ;

Eglen, RM .

NEUROPHARMACOLOGY, 1997, 36 (4-5) :621-629

[6] Do animal models of anxiety predict anxiolytic-like effects of antidepressants? [J].

Borsini, F ;

Podhorna, J ;

Marazziti, D .

PSYCHOPHARMACOLOGY, 2002, 163 (02) :121-141

[7] Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY 100,635, in the rat [J].

Bristow, LJ ;

O'Connor, D ;

Watts, R ;

Duxon, MS ;

Hutson, PH .

NEUROPHARMACOLOGY, 2000, 39 (07) :1222-1236

[8] 1-[2-[(heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists [J].

Bromidge, SM ;

Davies, S ;

Duckworth, DM ;

Forbes, IT ;

Jones, GE ;

Jones, J ;

King, FD ;

Blackburn, TP ;

Holland, V ;

Kennett, GA ;

Lightowler, S ;

Middlemiss, DN ;

Riley, GJ ;

Trail, B ;

Wood, MD .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (16) :1867-1870

[9]

Cassano G, 1999, EUR NEUROPSYCHOPHARM, V9, P250

[10] SEROTONIN FUNCTION IN ANXIETY .2. EFFECTS OF THE SEROTONIN AGONIST MCPP IN PANIC DISORDER PATIENTS AND HEALTHY-SUBJECTS [J].

CHARNEY, DS ;

WOODS, SW ;

GOODMAN, WK ;

HENINGER, GR .

PSYCHOPHARMACOLOGY, 1987, 92 (01) :14-24

← 1 2 3 4 5 6 7 8 →